merged_ozempic-kidney-disease.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not mention Type 1 diabetes in relation to Ozempic or chronic kidney disease; it only discusses Type 2 diabetes.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article does not mention a clinical trial led by Dr. Melanie Hoenig that demonstrated Ozempic reduces the need for kidney transplants by 30%.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>The article does not mention a specific blood pressure medication that, when combined with Ozempic, showed synergistic effects in slowing kidney decline.</other>

<question_number>4</question_number>
<answer>N/A</answer>
<other>The article does not specify a minimum threshold of cardiovascular mortality reduction required by the F.D.A. for Ozempic's expanded use.</other>

<question_number>5</question_number>
<answer>N/A</answer>
<other>The article mentions medications to manage iron, calcium, and vitamin D levels but does not state that Ozempic exacerbates a vitamin deficiency.</other>

<question_number>6</question_number>
<answer>N/A</answer>
<other>The article does not specify the number of years of clinical trial data submitted by Novo Nordisk to the F.D.A. for Ozempic's long-term safety.</other>

<question_number>7</question_number>
<answer>N/A</answer>
<other>The article does not identify a specific genetic marker predictive of severe gastrointestinal side effects from Ozempic.</other>

<question_number>8</question_number>
<answer>N/A</answer>
<other>The article does not mention a competing drug for chronic kidney disease that failed Phase 3 trials due to liver toxicity.</other>

<question_number>9</question_number>
<answer>N/A</answer>
<other>The article does not provide the total number of U.S. adults prescribed Ozempic for off-label weight loss.</other>

<question_number>10</question_number>
<answer>Gough</answer>
<other>Dr. Stephen Gough is the Novo Nordisk official mentioned in the article.</other>

<question_number>11</question_number>
<answer>24</answer>
<other>The article states that people with Type 2 diabetes and chronic kidney disease who took Ozempic had a 24 percent lower likelihood of experiencing a complication.</other>

<question_number>12</question_number>
<answer>reducing inflammation</answer>
<other>The article suggests that Ozempic may benefit the kidneys by reducing inflammation throughout the body.</other>

<question_number>13</question_number>
<answer>semaglutide</answer>
<other>The F.D.A. lists semaglutide, the compound in Ozempic, as currently in shortage.</other>

<question_number>14</question_number>
<answer>diet and exercise modifications</answer>
<other>The article mentions that doctors encourage lifestyle changes, including diet and exercise modifications, to help manage Type 2 diabetes.</other>

<question_number>15</question_number>
<answer>40 percent</answer>
<other>Roughly 40 percent of people with Type 2 diabetes are expected to develop chronic kidney disease, according to Dr. Gough.</other>

<question_number>16</question_number>
<answer>dialysis or a transplant</answer>
<other>The article indicates that patients treated with Ozempic had a reduced chance of requiring dialysis or a transplant.</other>

<question_number>17</question_number>
<answer>lifestyle changes</answer>
<other>The article mentions that doctors routinely encourage lifestyle changes, which can include diet and exercise modifications.</other>

<question_number>18</question_number>
<answer>cardiovascular issues</answer>
<other>The treatment is shown to lessen the risk of fatal cardiovascular outcomes alongside kidney decline.</other>

<question_number>19</question_number>
<answer>F.D.A.</answer>
<other>The F.D.A. is the federal agency responsible for approving the expanded use of Ozempic.</other>